Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 5%, platinib was included in the National Health Insurance Catalogue, and the 2.0 pipeline matrix continues to expand

The Zhitong Finance App learned that Cornerstone Pharmaceutical-B (02616) rose by more than 5%. As of press release, it had risen 5.57% to HK$6.07, with a turnover of HK$22.7042 million.

According to the news, Cornerstone Pharmaceutical recently announced that the company's RET inhibitor Pujihua® (platinib capsules, 100 mg) has been successfully included in the latest “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” published by China's National Medical Security Administration. The catalogue will be officially implemented on January 1, 2026. Up to now, Cornerstone Pharmaceuticals has successfully promoted the approval and marketing of 4 innovative drugs. Of these, 3 products have been registered and approved for marketing by Cornerstone Pharmaceuticals in China, and have been included in the national health insurance catalogue.

According to a research report released by Tianfeng Securities in August this year, it is expected that the release of platinib is expected to accelerate after it is included in medical insurance. Cornerstone Pharmaceuticals' preclinical pipeline includes more than nine potential drug candidates, including multi-specific antibodies and ADCs. It focuses on FIC/BIC research, covering various treatment fields such as oncology, autoimmunity, and inflammatory diseases. The company's innovative internal ADC technology platform features optimized proprietary connectors to improve the release of tumor selective payloads. The platform supports more than 2.0 ADC products in the pipeline, which is expected to provide continuous impetus for the company's future development.